)
Visual
test
Hepion Pharmaceuticals
Hepion Pharmaceuticals (HEPA) investor relations material
Hepion Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Transitioned from drug development to medical diagnostics, focusing on in-licensed diagnostic tests for celiac disease, respiratory multiplex, H. pylori, and HCC, with CE marks for EU sales but not US approval.
Wind-down and closure of ASCEND-NASH clinical trial due to insufficient funding; all clinical activities completed by August 2024.
Attempted merger with Pharma Two B Ltd. was terminated in December 2024 after Nasdaq declined to exclude historical losses from burn rate calculations.
Delisted from Nasdaq in May 2025 and transitioned to OTCQB Venture Market in June 2025.
Financial highlights
Net loss for Q3 2025 was $0.5 million, a significant improvement from $4.9 million loss in Q3 2024.
Net loss for the nine months ended September 30, 2025 was $7.6 million, compared to $11.6 million for the same period in 2024.
No revenues reported for the quarter or year-to-date; accumulated deficit reached $245.4 million as of September 30, 2025.
Research and development expenses dropped to $0.4 million for the nine months ended September 30, 2025, from $12.4 million in the prior year period, mainly due to clinical trial wind-down.
General and administrative expenses decreased to $2.2 million for the nine months ended September 30, 2025, from $5.7 million in the prior year period.
Asset impairment loss of $0.4 million recorded in 2025 related to the New Day license agreement.
Outlook and guidance
Expects continued significant losses and negative cash flows; additional capital required to fund operations and development of newly acquired diagnostic assets.
Uncertainty remains regarding timing and amount of potential revenue from EU-eligible diagnostic products.
Assess New Day asset impairment impact on strategy
Detail capital raise plans to resolve going concern
Explain impact of internal control weaknesses
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebMGL
Strong revenue growth offset by lower margins and profit; interim dividend declared. - 7 FebPGIL
Strong revenue and margin growth, with India set for further expansion and upgraded ratings. - 7 Feb504614
Strong revenue and profit growth in Q3 FY26, led by power and steel segments. - 7 FebCHEMPLASTS
Net losses widened and revenue fell year-over-year amid regulatory and market headwinds. - 7 FebSBIN
Q3 FY26 net profit reached ₹21,028.15 crore, driven by robust income and strategic divestments. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights.
Next Hepion Pharmaceuticals earnings date
Q4 202513 Apr, 2026
Hepion Pharmaceuticals
Next Hepion Pharmaceuticals earnings date
Q4 202513 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Hepion Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for liver diseases, particularly non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company’s lead drug candidate, based on cyclophilin inhibition technology, aims to target inflammation, fibrosis, and viral infections affecting the liver. The company is headquartered in Edison, New Jersey, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage